Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7823739 | 0.88 | TACR1 (0.71) | TACR1 | |
| SCHEMBL7824174 | 0.88 | TACR1 (0.61) | TACR1ERAP2 | |
| SCHEMBL7829988 | 0.87 | ERAP2 (0.62) | TACR1ERAP2 | |
| SCHEMBL7829857 | 0.86 | TACR1 (0.60) | TACR1 | |
| SCHEMBL7829075 | 0.81 | TACR1 (0.66) | TACR1 | |
| SCHEMBL7826751 | 0.80 | TACR1 (0.65) | TACR1 | |
| SCHEMBL7827819 | 0.78 | TACR1 (0.80) | TACR1 | |
| SCHEMBL8475617 | 0.78 | TACR1 (0.80) | TACR1 | |
| SCHEMBL7826625 | 0.78 | ERAP2 (0.68) | TACR1ERAP2 | |
| SCHEMBL27346673 | 0.78 | ERAP2 (0.68) | TACR1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0655442-B1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5883098-A | USED AS TACHYKININ ANTAGONISTS IN THE TREATMENT OF RESPIRATORY DISEASES, OPHTHALMIC DISEASES AND INFLAMMATORY DISEASES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-03-16 | — | — | US | disclosed |
| US-5670505-A | TACHYKIKIN ANTAGONIST FOR RESPIRATORY DISEASES, OPHTHALMIC DISEASES AND ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| EP-0655442-A1 | Piperazine derivatives as Tachykinin antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-05-31 | — | — | EP | disclosed |